Medcool's RapidCool technology:
This article was originally published in Clinica
Medcool has received US FDA 510(k) clearance to market its noninvasive RapidCool system for reducing head and body temperature where clinically indicated - eg in hyperthermic patients. The device uses a patented disposable helmet that directs agitated cold water to the scalp, plus standard body and neck pads to rapidly cool the head and body. It reduces temperature to a set point in the range of 32-37 degrees C, and does not interfere with other hospital procedures such as cardiac catheterisation. A growing body of research indicates that mild hypothermia, in the range of 32-34 degrees C, could have a protective effect, reducing damage from cardiac arrest, stroke, brain injury and other traumatic events, said the Wellesley, Massachusetts firm.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.